Coulter Partners places Chief Medical Officer and Head of R&D at Bausch Health
London, February 11, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (“Bausch Health”) and is pleased to announce the placement of Jonathan Sadeh M.D., M.Sc., as Executive Vice President, Chief Medical Officer and Head of R&D.
Bausch Health is a global company that develops, manufactures and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, and international pharmaceuticals.
Jonathan Sadeh brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb, he was responsible for multiple drug approvals in dermatology and gastroenterology and held several key roles including Senior Vice President and Global Programs Head for Immunology, Cardiovascular and Neuroscience, Immunology Therapeutic Area Head, as well as the China R&D Head. His experience spans leading global R&D programs at major pharmaceutical companies such as Bristol-Myers Squibb, Sanofi, AstraZeneca, and Schering-Plough.
"We are delighted to welcome Jonathan as our new Head of Research and Development," said Thomas J. Appio, Chief Executive Officer at Bausch Health. "His extensive experience and innovative vision will be invaluable as we continue to enhance our pipeline and strive for groundbreaking advancements."
In his new role, Jonathan will be responsible for overseeing the entire R&D process, working closely with Bausch Health’s scientists and engineers. He will set the strategic direction and ensure alignment with their overall goal of enriching lives through a relentless drive to deliver better health outcomes. We are confident that Jonathan will make a significant contribution to the company's success and commitment to being an innovative healthcare company.
